Objective:To assess the correlation of high mobility group box 1 (HMGB-1) with Organoleptic rating(OR),dental plaque index(PLI) and halitosis with chronic periodontitis.Methods:Serum samples from 20 halitosis patients,20 chronic periodontitis patients with oral malodor and 8 healthy controls were collected.The level of HMGB-1 in the serum was detected by ELISA.The OR and PLI were estimated by organoleptic method and periodontal examination respectively.The data were analyzed with SPSS 17.0.Results:The levels of HMGB1 in the serum from 2 groups of patients was significantly higher than that of the controls(P ＜0.01).The level of HMGB-1 in the patients of halitosis with chronic periodontitis was significantly higher than that of the halitosis patients(P ＜ 0.01).There was no statistical difference of OR between the 2 groups of patients(P ＞ 0.05).The PLI of the chronic periodontitis patients with oral malodor was significantly higher than that of halitosis patients (P ＜ 0.01).The correlation of HMGB1 with OR and PLI of 2 groups of patients were positively correlated(P ＜ 0.05 and 0.01 respectively),the OR of halitosis patients showed no relevant(P ＞0.05).Conclusion:HMGB-1 may be one of the important factors that result in chronic periodontal inflammation and stubborn bad breath.

BACKGROUND: Intensive phototherapy (IPT) and exchange transfusion (ET) are the main treatments for extreme hyperbilirubinemia. However, there is no reliable evidence on determining the thresholds for these treatments. This multicenter study compared the effectiveness and complications of IPT and ET in the treatment of extreme hyperbilirubinemia. METHODS: This retrospective cohort study was conducted in seven centers from January 2015 to January 2018. Patients with extreme hyperbilirubinemia that met the criteria of ET were included. Patients were divided into three subgroups (low-, medium-, and high- risk) according to gestational week and risk factors. Propensity score matching (PSM) was performed to balance the data before treatment. Study outcomes included the development of bilirubin encephalopathy, duration of hospitalization, expenses, and complications. Mortality, auditory complications, seizures, enamel dysplasia, ocular motility disorders, athetosis, motor, and language development were evaluated during follow-up at age of 3 years. RESULTS: A total of 1164 patients were included in this study. After PSM, 296 patients in the IPT only group and 296 patients in the IPT plus ET group were further divided into the low-, medium-, and high-risk subgroups with 188, 364, and 40 matched patients, respectively. No significant differences were found between the IPT only and IPT plus ET groups in terms of morbidity, complications, and sequelae. Hospitalization duration and expenses were lower in the low- and medium-risk subgroups in the IPT only group. CONCLUSIONS In this study, our results suggest that IPT is a safe and effective treatment for extreme hyperbilirubinemia. The indication of ET for patients with hyperbilirubinemia could be stricter. However, it is necessary to have a contingency plan for emergency ET as soon as IPT is commenced especially for infants with risk factors. If IPT can be guaranteed and proved to be therapeutic, ET should be avoided as much as possible.
Child, Preschool ; Exchange Transfusion, Whole Blood/adverse effects* ; Humans ; Hyperbilirubinemia, Neonatal/therapy* ; Infant ; Infant, Newborn ; Kernicterus/therapy* ; Phototherapy/methods* ; Retrospective Studies